BMS-986278

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

BMS-986278 is a potent lysophospholipid receptor antagonist (LPA1).

Study Purpose

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

Find a Clinical Trial



 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >